479 related articles for article (PubMed ID: 23489968)
1. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
2. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
4. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
6. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
10. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Wang Y; Zhao L; Huang Q; Peng Y
J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
[No Abstract] [Full Text] [Related]
11. Integrating incretin-based therapy into type 2 diabetes management.
Brunton SA
J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
[No Abstract] [Full Text] [Related]
12. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
13. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
14. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
15. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
16. Three new drugs for type 2 diabetes.
Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapies: review of current clinical trial data.
Peters A
Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Madsbad S; Krarup T; Deacon CF; Holst JJ
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
[TBL] [Abstract][Full Text] [Related]
20. The future of incretin-based therapy: novel avenues--novel targets.
Ahrén B
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
